Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI02130086
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
BI02130086 is a long-acting selective glucagon receptor (GCGR) agonist developed by Boehringer Ingelheim. It is being investigated in preclinical models of obesity and type 2 diabetes (T2D) to evaluate the therapeutic impact of normalizing insulin resistance and inducing weight loss. In experimental models of stroke in T2D mice, pre-stroke treatment with BI02130086 was shown to improve post-stroke functional recovery and reduce neuroinflammation, highlighting the potential of glucagon receptor agonism and weight management in improving stroke prognosis in patients with type 2 diabetes.
- Other names
- BI 02130086BI02130086BI-02130086
02
Targets
GCGR (Glucagon receptor)
Beyond the preview
Go deeper on BI02130086.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI02130086.